Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Letrozole as post-operative breast cancer therapy reduces recurrence, large study shows
January 26th, 2006
Post menopausal women with early invasive breast cancer may now benefit from Femara (letrozole) immediately after surgery. Femara was granted early approval of an adjuvant (post-surgery) license by the Medicines and Healthcare Products Regulatory Agency (MHRA). The threat of cancer returning is a major concern for many women following surgery and Femara has been shown to significantly reduce recurrence (Waldie E, et al. Clinical study report CFEM345D 019 (BIG 1-98): 2005. Novartis Pharma AG, Basel, Switzerland). The results of the BIG1-98 trial, a large published study involving over 8,000 women with breast cancer showed that women taking Femara...
Source: Women's Health Weekly (2006-01-26)
|
